Psychedelic Therapy Reimbursement

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply. These are temporary codes assigned...

In the midst of an expected FDA approval of MDMA-assisted therapy in 2024, BrainFutures has released a comprehensive guide for practitioners offering psychedelic-assisted therapy (PAT.)  BrainFutures is a national nonprofit that assesses and advances the practical...